Sell RIM!: Against ...
Health Care: Drugs
Arena Pharmaceuticals Inc. (ARNA: NASDAQ)
$6.43 0.03 | 0.47%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.15 | 0.58 | 0.98 |
| Price to Sales (TTM) | 114.88 | 4.62 | 1.42 |
| Price to Book (MRQ) | 28.15 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 37.65 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -14.90 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -16.40 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -44.20 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -23.40 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -8.37 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -46.69 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 7.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.50 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 1.92 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 1.96 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -487.48 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -8.73 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -51.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -55.30 | 2.20 | 2.50 |
| Return on Investment (TTM) | -73.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -76.20 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 41,289.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -360,538.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 5.50 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.40 | 0.40 |
Portfolios with ARNA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Userchrisnash69 Portfolio 1
- User1st Time out
- Userbio
- UserWIDELY HELD IN GAME
- Usermarket watch 2012
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserHoldings
- ContributorStocks Under-$10 Moving Hig...
Latest ARNA Headlines from TheStreet
- Stocks Under $10: Why I'm a Buyer
05.31.12 | 07:05 am - 4 Stocks Under $10 Making Big Moves 05.30.12 | 03:05 pm
- Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Loser 05.25.12 | 05:05 pm
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- Outlooks for Pfizer, Arena and Onyx Following Busy May 05.21.12 | 07:05 am
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- Stocks Under $10: Healthcare Name on Sale 05.17.12 | 07:05 am
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Winner 05.14.12 | 04:05 pm
- Mulling Arena Pharma's Future With Obesity Drug on Approval Path 05.14.12 | 03:05 pm
Press Releases for ARNA
- Arena Pharmaceuticals Investigated By Goldfarb Branham Law Firm LLP - Business Wire 10.08.10 | 09:10 am
- Girard Gibbs LLP Files Class Action Lawsuit Against Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) - Business Wire 09.29.10 | 05:09 pm
- Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) - Business Wire 09.28.10 | 02:09 pm
- Investor Notice: The Rosen Law Firm Announces Filing Of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA - Business Wire 09.22.10 | 06:09 pm
- Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 05:09 pm
- The Law Office Of Robbins Umeda LLP Announces An Investigation Of Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 12:09 pm
Partner Headlines for ARNA
- Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge? - Benzinga 05.31.12 | 12:05 pm
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Pre-Market Most Active for May 22, 2012 : QQQ, NOK, FB, BBY, TEF, BAC, SNY, NVO, VOD, AAPL, ARNA, ZNGA - NASDAQ 05.22.12 | 12:05 pm
- Pre-Market Most Active for May 17, 2012 : SNY, BAC, BUD, MT, MTL, WMT, QQQ, VOD, AAPL, DNDN, ZNGA, ARNA - NASDAQ 05.17.12 | 12:05 pm
- Pre-Market Most Active for May 16, 2012 : CTL, SNY, BAC, GE, NCT, MT, QQQ, ARNA, SINA, PETD, ZNGA, RIMM - NASDAQ 05.16.12 | 12:05 pm
- After Hours Most Active for May 15, 2012 : DFG, TPX, JCP, GSM, QQQ, BAC, ARNA, CCJ, AIG, VELT, INTC, NWSA - NASDAQ 05.15.12 | 08:05 pm
- Pre-Market Most Active for May 14, 2012 : BAC, CHK, NOK, BBVA, CS, SIRI, JPM, ARNA, QQQ, YHOO, AAPL, FRAN - NASDAQ 05.14.12 | 12:05 pm
- Arena Pharmaceuticals: FDA Approval Is Just The Beginning - Seeking Alpha 05.13.12 | 09:05 am
- Benzinga's Top Upgrades with Color for May 11, 2012 - Benzinga 05.11.12 | 12:05 pm
- Social Media Outlook for Wednesday May 9 (PDC, DIS, STEC, FOSL) - Benzinga 05.09.12 | 01:05 pm
